Company Investors Technology Careers Updates Events Contact Investment Opportunities Angiogenesis and mRNA splicing-related diseases constitute a large and growing market opportunity With changing population demographics, the incidence of both diabetes and age related macular oedema is increasing and new improved therapies are required to treat the neovascular changes at the back of the eye. Current therapies for both conditions requires intraocular injection of large molecules, so the market for Exonate’s small molecules as topical eye drop administration is compelling. The global cost of visual impairment due to age-related macular degeneration - Exonate’s first therapeutic target area of ophthalmology – is $343 billion, including $255 billion in direct health care costs and is the most invested in area of ophthalmology by venture capitalists. Treatment costs for non-DMO diabetic patients was US$ 6,801 in 2011, compared to US$ 14,678 for patients with DMO, a difference of almost $8000 per year per patient. This translates to an expected global DMO market of around $4 billion by 2025. Finance April 2014 - Seed investment £400K Oct 2015 – 2nd stage £800K Nov 2016 – 3rd stage £1.5M Feb 2017 - Wellcome Trust SDDI £4.9M Jan 2020 - Janssen collaboration Board members Sunil Shah - Chairman Professor David Bates - CSO Dr Catherine Beech OBE - CEO Professor Steven Harper - Medical Director Dr Chris Torrance – CEO Phoremost Ltd Dr John Kurek – Uniseed Dr Andrew Naylor – University of Nottingham Dr Sam Fazeli - Sam Fazeli Senior Analyst and EMEA head of Bloomberg Intelligence CAB Professor Lloyd Paul Aiello Professor Peter Campochiaro Professor Usha Chakravarthy Professor Robyn Guymer Investors Wellcome Trust Angel Co Fund University of Nottingham O2h Uniseed Cambridge Angels Parkwalk IpGroup Wren Martlet Get in touch with us Work with us to improve the treatment of patients with retinal vascular diseases CONTACT US Who we are Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need. Alternative mRNA splicing is modulated in disease states resulting in pathological blood vessel formation (angiogenesis) This is a key driver of disease progression in some ophthalmic conditions and cancers. Follow us on Social Media Useful links Career opportunities Technology Investors Contact Copyright © 2021 Exonate Privacy policy Designed and built by Onespacemedia